Kornimate/medical-research-clean huggingface dataset:
mucociliary clearance in stroke

Conditions: Stroke, Ischemic

Summary: stroke patients frequently suffer from stroke associated pneumonia. pathophysiologically speaking, dysphagia and central nervous system (cns)-injury induced immunosuppression largely contribute to the risk for pneumonia. in mouse models for stroke, the self-cleaning mechanisms of the lung are also affected by stroke, possibly further contributing to this risk. the investigators designed a pilot-study to examine the structural and functional integrity of the self-cleaning mechanisms of the lung in stroke patients.

survival and functional outcome of stroke is strongly depending on the occurence of pneumonia (stroke-associated pneumonia, sap). early diagnose and treatment of sap is paramount in the treatment of stroke patients. while dysphagia strongly contributes to its pathogenesis, recent years have also shown a strong risk-modulation by cns injury induced immunosuppression, making stroke patients more susceptible to sap. additionally, murine models of stroke showed changes in mucociliary clearance as possible contributors to sap. it remains unclear, whether structural integrity and mucociliary clearance of the respiratory epithel change in stroke patients, and whether these changes might contribute to the occurence of sap. therefore, the investigators designed this exploratory observational pilot-study to examine the structural and functional integrity of respiratory epithel in severely affected stroke patients and correlate these findings to immune phenotyping and occurence of sap. the investigators will conduct bronchoscopy in severely affected stroke patients to collect histological samples in order to evaluate multiple tissue predictors, as well as perform optical coherence tomography to examine ciliary kinetics in-vivo. the investigators will furthermore perform serum and plasma immune phenotyping, record occuring pneumonias and correlate these data in order to identify possible predictors of pneumonia.

Eligibility criteria:
inclusion criteria: * age ≥18 years * informed consent signed by patient or legal representatives * acute ischemic stroke within the past 2 weeks (except the control group) * indication for diagnostic or therapeutic bronchoscopy exclusion criteria: * confirmed lung malignancies or specific inflammations of the lungs * pneumonia (only control group) * autoimmune diseases of respiratory system (only control group) * chronic inflammatory diseases of respiratory system (only control group) * chronic obstructive pulmonary disease (copd) and spastic diseases of respiratory system (only control group) * patients being committed to psychiatric institutions or prisons

Keywords: acute ischemic stroke bronchoscopy
covid-19 : neutralizing human monoclonal antibodies against sars-cov-2

Conditions: COVID

Summary: rationale : the emergence of the novel, pathogenic sars-coronavirus 2 (sars-cov-2) threatens public health. to date, there are no effective drug option to prevent the infection, nor therapeutics for controlling the deadly covid-19. however, the majority of patients infected with sars-cov-2 eliminate the virus by mounting a protective antiviral immune response, associated in particular with the production of neutralizing antibodies. neutralizing antibodies could be of particular interest for therapeutic purposes, but also for preventive applications, to protect people who have never been in contact with the virus, or immunocompromised patients. the objectives of this study are : * to generate human monoclonal antibodies neutralizing sars-cov-2 from immortalized b cells of convalescent patients. * to compare the serological profiles between convalescent patients that develop mild or uncomplicated illness and convalescent patients that develop a more severe disease, that required hospitalization and oxygen support. * to compare for each patient the neutralizing efficiency of plasma to the neutralizing capacities of the monoclonal antibodies generated with immortalized b cells.


Eligibility criteria:
inclusion criteria: * patient over 18 years old * patient who signed the study consent form * convalescent patient (at least 12 days after the onset of symptoms), having been sampled at hospices civils de lyon for a suspected infection with sars-cov-2, confirmed by pcr. exclusion criteria: * patient treated with rituximab * patient treated with immunoglobulins * patient over 18 years old, subject to a legal protection measure (guardianship or trusteeship) * patient deprived of liberty * pregnant or lactating woman * patient not affiliated to a social security scheme or beneficiary of a similar scheme.
vaginal estrogen on postpartum atrophy, perineal pain, and sexual function

Conditions: Vaginal Atrophy

Summary: pilot randomized, placebo-controlled trial of nulliparous postpartum women with a perineal laceration following a term vaginal delivery comparing vulvovaginal atrophy symptoms between women using vaginal estrogen in the postpartum period with those using placebo.

the overall goal of this study is to determine whether there are benefits to use of low-dose vaginal estrogen in the postpartum period. dyspareunia and vaginal/perineal pain are well-known sequelae after vaginal delivery. however, the contribution of postpartum vaginal atrophy to these issues is largely unknown. although the relationship between lactation, relative estrogen deprivation, and vulvovaginal atrophy has been established, there is a paucity of data regarding on the prevalence of vulvovaginal atrophy symptoms in the postpartum period. additionally, although the benefits of vaginal estrogen in postmenopausal atrophy are well-established, the benefits in the postpartum period are unknown.

Eligibility criteria:
inclusion criteria: * females \>18 years old with at least one prior prenatal care appointment affiliated with the ohio state university wexner medical center; nulliparous; 1-2 days status post \>37 weeks and 0 day vaginal delivery with at least a second degree perineal laceration; english-speaking and able to provide informed consent. exclusion criteria: * allergies to estradiol cream or its constituents; a vaginal delivery associated with a intrauterine fetal demise or neonatal death; inability to complete questionnaires in english or comply with study protocol; and inability to apply vaginal cream independently. the following medical conditions and diagnoses are also exempted: undiagnosed abnormal vaginal bleeding, known or suspected estrogen-dependent neoplasia, active or history of deep venous thrombosis or pulmonary embolism, active arterial thromboembolic disease, known liver dysfunction or disease, known protein c, protein s, or antithrombin deficiency, or other known thrombophilic disorders.

Keywords: postpartum, local estrogen
double blind placebo controlled bellis perenis and arnica montana as a drug for pph

Conditions: Hemorrhage

Summary: to look at the antihemmorhagic effect of 2 homeopathic drugs in women post delivery bellis perenis and arnica montana

to look at the antihemmorhagic effect of 2 homeopathic drugs in women post delivery bellis perenis and arnica montana compare it with placebo

Eligibility criteria:
inclusion criteria: * healthy women during delivery exclusion criteria: * scarred uterus, multifetal ,multiparty,bleeding problems,cesarean sectons,chorioamnionitis

Keywords: post partum hemmorhage,arnica montana,bellis perenis
robot-assisted versus laparoscopic surgery for mid/low rectal cancer

Conditions: Rectal Carcinoma

Summary: the purpose of this study is to evaluate the safety and oncological feasibility of robot-assisted surgery for mid/low rectal carcinoma compared with laparoscopic surgery.

laparoscopic surgery as the treatment for colon cancer has been widely recognized. but its use for rectal cancer is still controversial. previous trials have shown that although the long-term survival outcomes were similar, laparoscopic surgery did not reach the non-inferiority in terms of local tumor radical resection, compared with open surgery. robotic techniques are considered to improve the quality of surgery with three-dimensional vision, stable camera platform and flexible robotic arms. meta-analyses have shown that compared with laparoscopic surgery, robotic surgery could improve surgical quality in terms of open conversion, circumferential resection margin, postoperative complications, postoperative recovery, and quality of life, with similar long-term survival. however, these evidences mainly came from retrospective studies and small-scale randomized controlled trials with low quality. there still needs high-quality clinical trials to confirm the advantages of robotic surgery for rectal cancer.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) class i - iii; * histologically proved rectal adenocarcinoma; * inferior tumor edge ≤ 10 cm from anal verge, measured by rigid rectoscopy; * tumor assessed as ct1-t3 (mesorectal fascia not involved) n0-1, or yct1-t3 nx after preoperative radio- or chemoradiotherapy, measured by pelvic mri; * no evidence of distant metastases; * no other malignancies in medical history except adequately treated basocellular carcinoma of the skin or in situ carcinoma of the cervix uteri; * suitable for both robotic and laparoscopic surgery; * informed consent. exclusion criteria: * tumors assessed as clinical complete response after preoperative radio- or chemoradiotherapy; * tumors assessed as ct1n0 and suitable for local excision; * signs of acute intestinal obstruction, bleeding or perforation needing emergency surgery; * multiple colorectal tumors or other schedules needing for synchronous colon surgery; * hereditary colorectal cancer (familial adenomatosis polyposis, lynch syndrome, etc.); * co-existent inflammatory bowel disease; * pregnancy or lactation; * patients received treatment other than preoperative radio- or chemoradiotherapy.

Keywords: minimally invasive surgical procedures robotic surgical procedures laparoscopic surgical procedures rectal cancer intraoperative complications postoperative complications recovery of function recurrence disease progression survival
clinical efficacy and safety evaluation of teneligliptin in type 2 diabetes who have inadequate glycemic control with empaglyflozin 25 mg and metformin

Conditions: Type 2 Diabetes

Summary: the objective of this study is to evaluate the efficacy and safety of teneligliptin 20 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic control with empaglyflozin 25 mg and metformin


Eligibility criteria:
inclusion criteria: * patients with type ii diabetes mellitus aged 19 years or older * subjects with 7.0%≤hba1c≤10.5% at screening visit * subjects with fasting plasma glucose ≤ 270mg/dl at screening visit exclusion criteria: * subjects with type 1 diabetes mellitus or secondary diabetes * subjects with history of diabetic ketoacidosis, diabetic coma or pre-coma, lactic acidosis, and acute or chronic acidosis within 6 months prior to the screening visit * subjects who have been administered with weight-loss drug (e.g., orlistat, phentermine/topiramate, lorcaserin) * body mass index greater than 40 kg/m2 at the screening visit * subjects with heart failure (class iii-iv of nyha classification) or arrhythmia that requires treatment
leuprolide in determining the cause of gonadotropin deficiency

Conditions: Hypogonadism

Summary: rationale: the body's response to one injection of leuprolide may provide more information than the standard test for gonadotropin deficiency in determining whether the cause of gonadotropin deficiency is related to the hypothalamus or the pituitary gland. purpose: randomized double-blinded clinical trial to study the effectiveness of leuprolide in determining the cause of gonadotropin deficiency.

protocol outline: this is a randomized, double blind study. patients are randomized to receive leuprolide acetate or gonadotropin releasing hormone (gnrh) first, then cross over to receive the other test. patients receive one subcutaneous injection of leuprolide acetate or gnrh, then have blood samples drawn periodically. one month later, patients receive the other test. another cohort of patients are randomized to receive leuprolide acetate once daily on days 0, 4, and 8, or days 0, 5, and 10. patients are followed for up to 2 years. completion date provided represents the completion date of the grant per oopd records

Eligibility criteria:
protocol entry criteria: --disease characteristics-- * prepubertal children with constitutionally delayed puberty at least 2 years retardation of bone age spontaneously progress into puberty within 1 year boys: testes long diameter 2.5-3.5 cm and plasma testosterone 40-300 ng/dl girls: breast development, but premenarcheal or hypogonadotropinism delayed onset of pubertal milestones associated with anterior panhypopituitarism or kallman's syndrome no spontaneous progression into puberty within 2 years after 6 months replacement sex steroid treatment --prior/concurrent therapy-- * at least 2 months since prior sex hormone treatment --patient characteristics-- * age: 14-18 for children with hypogonadotropinism 9-13 for normal children * other: no chronic systemic disease no metabolic disease no endocrine disease no growth hormone deficiency

Keywords: endocrine disorders hypogonadism rare disease
the oil, fats and oleogel study

Conditions: Glycaemic Response and Energy Balance

Summary: the aim of this study is to compare the effects of dietary fats, ingested in two physical forms, on acute energy balance, appetitive, and glycemic responses of healthy normal (bmi 18-24.9 kgm-2) or overweight (bmi\>25kgm-2) adults.

this will be a randomised, crossover study. randomisation will be performed with an online randomisation software (www.randomizer.org). participants will be screened (1 screening visit) and attend five test visits conducted in a whole room calorimeter (wrc). during each test visit, participants will arrive at the laboratory after an overnight fast, enter the wrc and rest for 15 minutes in a supine position,have their resting energy expenditure (ree) measured for 30 minutes and consume congee and juice alone(control), or with one of the 4 dietary fats: sunflower oil (so) or gel (sg) and coconut oil (co) or gel (cg) (total 5 test visits). post-meal energy expenditure, fat oxidation, glycemia and appetite (visual analog scales) will be measured continuously for 3 hours in wrc, followed by a meal challenge where participants will eat until sated. participants will return and repeat the protocol until all fat types and forms are completed.

Eligibility criteria:
exclusion criteria: * people with major chronic disease such as heart disease, cancer, hypertension or diabetes mellitus * people with known food allergies, due to potential traces of allergens found in the commercially available food product used in our study (knorr's instant congee) * people who are claustrophobic * individuals who are taking insulin or drugs known to affect glucose metabolism, appetite, and body fat distribution * have weight change of \>5kg in the past 3 months * people with a major medical or surgical event requiring hospitalization within the preceding three months * people who are on a weight loss regime * individuals with the presence of disease or drugs which influence digestion and absorption of nutrients
establishment of drug-induced liver injury databases and application of circulating microrna(mirna)

Conditions: Drug-induced Liver Injury

Summary: the purpose of the study is to establish drug-induced liver injury databases in china, make criteria for chinese drug-induced liver injury patients and evaluate the application of certain circulating mirna in diagnosis or treatment of drug-induced liver injury.

firstly, this study collects some retrospective data. analyse these data and establish certain unique diagnostic criteria for chinese. then collect prospective data and validate the criteria. otherwise,collect blood sample or other sample of the patients and study certain mirna in diagnosis or treatment of drug-induced liver injury.

Eligibility criteria:
inclusion criteria: * males and females between the age of 18 to 70 years * women in child-bearing period taking some contraception measures * patients with onset of acute liver injury attributed to antituberculosis drugs or antineoplastic drugs, roussel uclaf causality assessment method（rucam ） score≥6 * written informed consent can be obtained, some patients agree with liver biopsy exclusion criteria: * viral hepatitis * alcoholic liver disease or non-alcoholic liver disease * wilson's disease or other inherited metabolic liver diseases * auto-immune liver diseases * any dysfunction of liver * malnutrition * chronic diseases such as hiv,severe heart diseases, severe brain diseases or chronic kidney diseases * patients who can not complete follow-ups on time
su011248 for platinum-refractory urothelial cancer evaluation trial

Conditions: Urothelial Cancer; Bladder Cancer; Adult

Summary: the purpose of this study is to find out if su011248 works and if it is safe in patients with advanced transitional cell carcinoma.

the study objectives include the determination of the antitumor effect of su011248 in patients with urothelial transitional cell carcinoma and to also determine the toxicities and tolerability of su011248 in patients with urothelial transitional cell carcinoma who have failed or are intolerant to cisplatin-based chemotherapy. the primary endpoint of the study is to compare progression free survival at 4 months in patients who received su011248 plus bsc versus patients who received placebo plus bsc the secondary endpoint is to compare the objective response rate and duration of response in patients who received su011248 plus bsc versus patients who received placebo plus bsc, to describe the qol and safety profile of su011248 when compared to placebo and to describe the overall survival in patients who received su011248 plus bsc versus patients who received placebo plus bsc

Eligibility criteria:
inclusion criteria: * histologically/cytologically proven inoperable, metastatic or recurrent transitional cell carcinoma of the urothelial tract * mixed histology with predominant tcc allowed. * failed, intolerant or ineligible for cisplatin based chemo * measurable disease (recist)not previously irradiated. * recovered from previous acute treatment to grade 1(ctcae vers. 3.0) * no weight loss \>/- 10% within 28 days of day 0 * adequate organ function exclusion criteria: * adenocarcinoma, squamous carcinoma or other histology without any components of transitional carcinoma. * small cell histology * more than one previous systemic chemo * excised metastases without remaining measureable disease * prior therapy with angiogenesis inhibitors

Keywords: urothelial cancer targeted therapy antiangiogenesis therapy su011248 clinical trial
comparison of two pain-treatment techniques after cesarean section

Conditions: Cesarean Section; Pain Management; Neuropathic Pain

Summary: comparison of two types of analgesia after cesarean section. all patients will anaesthetised with spinal technique. ultrasound-guided transversus abdominis plane or quadratus lumborum block to treat postoperative pain. postoperative pain will measured with visual-analogue scale (vas). 1, 2, 6 months after surgery each patient will be called to assess neuropathic pain with neuropathic pain symptom inventory (npsi).

written consent will be obtained before the cesarean section. only subarachnoidally anaesthetised patients may participate in the study. pencil-point spinal needle and bupivacaine (marcaine heavy spinal 0.5 %) will be used. at the end of surgery ultrasound-guided regional block will be performed. each patient will be randomly allocated to one of the treated group: transversus abdominis plane block (tap) or quadratus lumborum (ql). patients receive 0.2 ml of local anesthetic solution (0.25 % bupivacaine) on each side. postoperative pain will be measured with vas (visual-analogue scale) 2, 4, 8, 12 and 24 hours after the end of operation. paracetamol, metamizol, ketoprofen may be given as required. whenever pain exceeds 40 (vas) 5 mg of morphine will be given intravenously (maximum two dosages per day). 1, 3, 6 months patients will be called to assess neuropathic pain. neuropathic pain symptom inventory (npsi) will be used.

Eligibility criteria:
inclusion criteria: * obtained consent * singleton pregnancy * subarachnoid anaesthesia exclusion criteria: * coagulopathy * allergy to to local anesthetics * depression, antidepressant drugs treatment * epilepsy * usage of painkiller before surgery * addiction to alcohol or recreational drugs

Keywords: acute pain transversus abdominis plane block quadratus lumborum block neuropathic pain
eeg recordings and analysis in parkinson's patients: towards adaptive deep brain stimulation by machine learning

Conditions: Parkinson Disease

Summary: the objective of this protocol is to obtain on parkinson's disease more accessible therapeutic targets than deep brain stimulation (hfs-stn), the neurosurgical treatment for this pathology. this study will pave the way for new forms of adaptive processing for the hfs-stn. it could become functionally coupled to a minimalist eeg centred on the motor cortex and to software for decoding, live or slightly delayed, classes of movements performed. on the one hand, this device could be used as a sensor of the quality of the information transmitted by the cortical network, thus allowing the selection of the optimal parameters of the hfs-stn on the basis of the movement decoding score. on the other hand, this device could lead to adapting the hfs-stn treatment over time by regularly calculating the recognition scores of the different movements performed and comparing them to the initial scores.

one of the therapies for parkinson's disease, a condition affecting nearly 150,000 patients in france, is the invasive neurosurgical implantation of high-frequency deep brain stimulation of the subthalamic nuclei (hfs-stn). although hfs-stn is very effective, the underlying mechanisms are still relatively poorly understood, particularly at the cortical level, a region that could become an alternative therapeutic target because it is easier to access. this study aims to measure the changes induced by the antiparkinsonian drug treatment and the hfs-stn on the encoding and transmission of motor information at the level of the motor cortex, thanks to the recording of the electroencephalogram of patients. these recordings, made during the performance of certain movements, will be subjected to an analysis using "machine learning" methods that will make it possible to decode the identity of the movement performed more or less efficiently.

Eligibility criteria:
inclusion criteria: patients : 1. patient over 18 years of age 2. patient meeting the clinical diagnostic criteria for parkinson's disease (postuma et al, mov dis, 2015) 3. signed consent to participate in the study 4. absence of cognitive impairment (moca\>24) 5. affiliation to a french social security scheme healthy volunteer : 1. healthy volunteer over 18 years of age 2. signed consent to participate in the study 3. absence of cognitive disorders (moca\>24) 4. affiliation to a french social security system exclusion criteria: patients : 1. patient refusal to participate 2. pregnancy or breastfeeding in progress 3. participation in another therapeutic interventional study 4. patient under guardianship or curatorship 5. person subject to a legal protection measure healthy volunteers : 1. refusal of the healthy volunteer to participate 2. pregnancy or breastfeeding in progress 3. participation in another therapeutic interventional study. 4. patient under guardianship or curatorship 5. person subject to a legal protection measure

Keywords: eeg montreal cognitive assessment mds-updrs iii mds-updrs iv